CA-IL12 / Cytonus Therap - LARVOL DELTA

Interim results from a comparative oncology safety study evaluating intravesical chitosan/interleukin‑12 immunotherapy in client-owned dogs with invasive urothelial carcinoma (SITC 2025) - "Serum cytokine analyses reveal minimal systemic immune responses. Additional dogs will be enrolled to finalize a recommended dose to be used in a planned Phase II activity study.Acknowledgements This research is supported by a grant from the National Cancer Institute (U01CA272258).Ethics Approval Studies involving animals were approved by the IACUC at NC State University (22-229, 25-190).Abstract 855 Table 1View inline•Open as popupAdverse events following intravesical chitosan/interleukin-12 immunotherapy in client-owned dogs with invasive urothelial carcinomaAbstract 855 Figure 1Request permissionsHematologic and biochemical safety/toxicity marker in dogs following treatment with intravesical CS/caIL-12"

Clinical • IO biomarker • Bladder Cancer • Oncology • Solid Tumor • Urothelial Cancer • IL12A

Adoptive transfer of membrane-restricted IL-12-TCR T cells promotes antigen spreading and elimination of antigen-negative tumor variants. (PubMed, J Immunother Cancer) - "Expression of caIL-12 by tumor-targeting T cells demonstrated therapeutic effect against target-antigen-negative tumor variants, primarily through the induction of antigen spreading. These findings highlight the potential of caIL-12 to address challenges of antigen escape and tumor heterogeneity that may limit the efficacy of T-cell therapy against solid tumors."

Journal • Hematological Malignancies • Lung Cancer • Melanoma • Oncology • Solid Tumor • Targeted Protein Degradation • CD8 • IL12A

Adoptive transfer of membrane-restricted IL-12-TCR T cells promotes antigen spreading and elimination of antigen-negative tumor variants (SITC 2024) - "These findings highlight the potential of caIL-12 to address challenges of antigen escape and tumor heterogeneity that may limit the efficacy of T-cell therapy against solid tumors. Ethics Approval All experiments were conducted with the approval of the National Cancer Institute Animal Care and Use Committee."

Hematological Malignancies • Lung Cancer • Melanoma • Oncology • Solid Tumor • CD8 • IL12A

Interleukin‐12 antibiotic resistance gene‐free plasmids for gene electrotransfer‐mediated cancer immunotherapy (ESGCT 2023) - P1 | "A commercially available plasmid encoding a mouse IL -12 (pORF-mIL-12 (p40p35), Invivogen) with an ampicillin resistance gene in the backbone was used as a control...Nevertheless, IL -12 expression from all four plasmids was detected in all three cell lines, confirming that even 2 copies per cell are sufficient for transgene expression.We demonstrated that our mouse, canine, and human antibiotic resistance gene-free IL -12 plasmids are stably maintained in bacteria and support sufficient IL -12 expression after GET in vitro. The plasmids encoding mouse and human Il-12 orthologs have now proceeded to in vivo evaluation, while the plasmid encoding canine IL-12 is currently being used in a clinical study in client-owned dogs with various solid tumors."

IO biomarker • Basal Cell Carcinoma • Gene Therapies • Melanoma • Non-melanoma Skin Cancer • Oncology • Solid Tumor • IL12A

Cytonus Therapeutics to Present Preclinical Data for Cargocyte CA-IL-12 for Treating Immune Checkpoint Inhibitor-Resistant Late Stage Metastatic Cancers at AACR 2022 (Businesswire) - "Cytonus Therapeutics Inc...announces that their CSO, Dr. Richard Klemke Ph.D., will present the preclinical progress made on Cytonus’ lead Cargocyte product candidates at the annual AACR meeting in New Orleans...Dr. Klemke will share data demonstrating striking infiltration of engineered Cargocytes into solid tumors in in vivo models of metastatic Triple Negative Breast Cancer (TNBC), localizing and synthesizing the company’s proprietary Interleukin twelve (IL-12) construct. Furthermore, Dr. Klemke will share in vivo data demonstrating the efficacy of tumor-localized activity of CA-IL-12 in reducing tumor burden, particularly in combination with immune checkpoint inhibitors."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer